ILLUMINATE Trial

Revision as of 11:58, 18 September 2013 by Rim Halaby (talk | contribs) (→‎Methods)
Jump to navigation Jump to search

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

ILLUMINATE Trial On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of ILLUMINATE Trial

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on ILLUMINATE Trial

CDC on ILLUMINATE Trial

ILLUMINATE Trial in the news

Blogs on ILLUMINATE Trial

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for ILLUMINATE Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Objective

Raising HDL levels by a combination of torcetrapib, a CETP inhibitor, and atorvastatin, an HGM-CoA reductase inhibitor.

Dates

Start Date

August 23, 2004

End Date

Premature Termination on December 2, 2006. Data collection continued till July 15, 2007.

Methods

  • Phase III trial
  • Prospective, randomized, multicenter, double-blind clinical trial that recuited 15,067 patients.
  • Inclusion criteria: Patients aged 45-75 years who have a history of cardiovascular disease 30 days to 5 years before screening; patients who have type 2 diabetes mellitus that meet criteria of the American Diabetes Association or receive anti-diabetic agents, even without previous cardiovascular disease.
  • Exclusion criteria: Unstable medical condition, life expectancy less than 5 years, LDL-C levels < 100 mg/dL, those not receiving anti-lipidemic medications, if LDL-C target level not achieved at termination of run-in period, and those who have cardiovascular event during run-in period or uncontrolled hypertension: SBP>140 mmHg or DBP>90 mmHg,
  • Run-in period: 4-10 weeks
  • Cardiovascular disease was defined as myocardial infarction, stroke, acute coronary syndrome, unstable angina, peripheral vascular disease, and cardiac revascularization.
  • Two arms of the study: Atorvastatin alone or atorvastatin plus torcetrapib 60 mg. Dosage of atorvastatin was determined while achieving of target LDL-C levels during run-in period and can be changed during the study period according to LDL-C levels.
  • Primary Outcome was defined as the time to first “cardiovascular event”.
  • “Cardiovascular event” defined as death from coronary artery disease, nonfatal myocardial infarction, stroke, or hospitalization for unstable angina. Procedure-related deaths and events were excluded.
  • Secondary outcome: time to the first occurrence of a primary outcome. Time to death regardless of the etiology, change from baseline LDL and HDL levels.
  • Outcomes based on 1,3,6,9, and 12 months scheduled visits.

Results

Study Outcomes

Conclusion

References